High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
about
An update of current treatments for adult acute myeloid leukemiaProgress in acute myeloid leukemiaFuture prospects of therapeutic clinical trials in acute myeloid leukemia.Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents.Molecular therapy for acute myeloid leukaemia.SLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro studyPossible benefit of consolidation therapy with high-dose cytarabine on overall survival of adults with non-promyelocytic acute myeloid leukemiaEffect of high dose cytosine arabinoside on quantitative EEG in patients with acute myeloid leukemia.Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups.FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients.Chemotherapy options for previously untreated acute myeloid leukemia.Return to work and work-related disability among AML survivors.Acute myeloid leukemia--major progress over four decades and glimpses into the future.Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?Ultrasonography-driven combination antibiotic therapy with tigecycline significantly increases survival among patients with neutropenic enterocolitis following cytarabine-containing chemotherapy for the remission induction of acute myeloid leukemia.Acute Myeloid Leukemia: How Do We Measure Success?Brazilian guidelines on hematopoietic stem cell transplantation in acute myeloid leukemia.Clonal evolution in therapy-related neoplasms.Copy-number analysis identified new prognostic marker in acute myeloid leukemia.Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989-2012.Role of low dose cytarabine in elderly patients with acute myeloid leukemia: An experienceLow-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of theComparison of the effects of early intensified induction chemotherapy and standard 3+7 chemotherapy in adult patients with acute myeloid leukemia.Emerging therapeutic modalities for acute myeloid leukemia (AML) in older adults.A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.Acute myeloid leukaemia.Clofarabine-based chemotherapy as a bridge to transplant in the setting of refractory or relapsed acute myeloid leukemia, after at least one previous unsuccessful salvage treatment containing fludarabine: a single institution experience.Precision therapy for acute myeloid leukemia.Cytarabine and daunorubicin for the treatment of acute myeloid leukemia.Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MPrognostic significance of constitutive phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase phosphorylation in acute myeloid leukemia.Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia).Social preferences for health states associated with acute myeloid leukemia for patients undergoing treatment in the United Kingdom.Dissecting causes for improved survival among patients with acute myeloid leukemia in two different eras receiving identical regimens in sequential randomized studies
P2860
Q26776396-7FB5E3FF-7F91-4F40-A6D2-F125B7D279FDQ27024006-A55DFA8C-2ADA-41C2-962A-4B6930B9E623Q30244168-79613A01-7E75-4C98-BEF7-A1C129CCB7AEQ33873351-743013AB-402A-4185-8CCC-049C7CAF8A1BQ33925672-CFBF6E71-29AF-4294-AB2D-F42F2F6DAB99Q34528361-B88A4E67-FC36-472F-8A9A-FA9D6A0DA6FBQ35062514-13EF6782-0E21-4F74-821B-67CEC8412D8DQ36723848-AE054398-6F92-4732-9E31-FF996B2CFE05Q36727867-C01A4E33-1B73-45E4-9610-606BD29844CCQ37580317-B5378F64-C6A8-4895-BAB0-ED0F67A68D65Q37624593-5132A39B-1427-4B9C-AE3D-12EEA33A0C58Q38419657-8F1CE50C-1131-4134-AC23-E94EDFD1D615Q38585930-6045A601-F849-457D-AB29-C53F038A838AQ38624682-319D7BFA-63C2-4110-9E49-79F233B74DD8Q38644941-861B641B-5D9E-43EF-AE05-1E7714C5C56FQ38664735-9B15C354-D146-4868-834B-C5CB98EF8F32Q38757179-CBAB10AB-47FA-41F2-9B58-E92429B2F9BCQ38948650-FEDE6AFC-D466-498D-8F36-F11A0BB1C58BQ38952815-8DABED79-98F7-4C49-BCE3-34C92C734003Q39026726-D52B48C0-941C-4E9A-A995-9E109B71BDE9Q39337506-29FFEC52-E50B-4A71-B97D-9DEBCFDBD283Q39601810-4075F467-7BE1-48F4-9F98-35E4270A196CQ40727176-81074B96-1B03-40AF-94D3-422A3A53C3DEQ41839446-62DC48BA-B93F-4D5C-98EE-8F19948FCAD3Q42325009-933C4B55-DB4A-4419-9BFF-002CBC6BDBF9Q42377773-45C080E4-3733-44F5-9EFF-35943BD3B78CQ46168137-7105A6EC-59C6-4D08-AA1F-1ED10687E1D7Q46744333-48ADFDFA-8297-4B9A-B4B1-5F24A2683A0DQ47432401-3B505BCE-66FE-4AC4-81F2-A3B4A2EF6005Q48215705-B8BE886B-C2F7-4A31-BBB1-1266E041A4BDQ49534332-63DCBB09-0A8A-4E25-BACA-995D16BF306CQ50090381-3A2E7D13-C371-49CF-B0F3-1502CC4CF899Q50923400-2F3479BD-4C25-41B4-AE81-9E1D2C522002Q51098678-E0A79A35-0561-41E2-BBFA-F74C4FEF4D57Q54307737-C0E87C14-AEC2-43F8-B665-4A9F56DE6B8EQ54964566-41758043-A40C-4218-8DC7-524156D12268Q55250106-817FE1A4-46A0-4C8E-ADCA-F109A6374CA2Q58718483-EE1F20FD-A4F4-4AB2-8B63-DA93D74BD301
P2860
High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
High-dose cytarabine in induct ...... the EORTC-GIMEMA AML-12 trial.
@ast
High-dose cytarabine in induct ...... the EORTC-GIMEMA AML-12 trial.
@en
type
label
High-dose cytarabine in induct ...... the EORTC-GIMEMA AML-12 trial.
@ast
High-dose cytarabine in induct ...... the EORTC-GIMEMA AML-12 trial.
@en
prefLabel
High-dose cytarabine in induct ...... the EORTC-GIMEMA AML-12 trial.
@ast
High-dose cytarabine in induct ...... the EORTC-GIMEMA AML-12 trial.
@en
P2093
P50
P356
P1476
High-dose cytarabine in induct ...... the EORTC-GIMEMA AML-12 trial.
@en
P2093
Andrea Camera
Anne Hagemeijer
Boris Labar
Constantijn J M Halkes
Daniela Cilloni
Domenico Magro
Dominik L D Selleslag
Dominique Bron
Erik W A Marijt
Francesco Fabbiano
P304
P356
10.1200/JCO.2013.51.8571
P407
P577
2013-12-02T00:00:00Z